Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (143)	5/21/1999 7:32:00 AM
From: Jim Oravetz	Read Replies (1) \| Respond to of 370

DJ Vion Pharm 1Q Losses 18c A Share Vs 32c Vion Pharmaceuticals Inc. New Haven, Conn. 1st Quar March 31: 1999 1998 Revenue $371,414 $274,842 Net income (2,432,229) (2,506,220) Avg shrs (basic) 14,034,943 9,891,509 Shr earns (basic) Net income (.18) (.32) Shr earns (diluted) Net income 0.00 0.00 Figures in parentheses are losses. Vion Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops and commercializes products to treat cancer and viral diseases. DJ Novavax/Pres/CEO-2: Spears Was Vion Pharma Pres/CEO Dow Jones Newswires COLUMBIA, Md. -- Novavax Inc. (NOX) named John A. Spears president and chief executive, replacing Mitchell J. Kelly, who served on an interim basis. In a press release Monday, the biopharmaceutical company said Spears was also named a director. Spears was previously president and chief executive of Vion Pharmaceuticals Inc. (VION), Novavax said Sorry about the formatting of the table. Can not figure out how to get it right! Ugh. Jim